Clinical trial NCT03920072: Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
Official title: A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: X-linked Hypophosphatemia
Keywords: Crysvita
Burosumab
X-linked Hypophosphatemia (XLH)
PHEX Gene Mutation
PHEXdb
Lead sponsor: Kyowa Kirin Pharmaceutical Development Ltd
Sponsor class: INDUSTRY
First posted: 2019-04-18
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Open-label, international, multicenter
Primary purpose: TREATMENT

Brief summary: This is phase 3b open-label, international, multicenter study to continue to monitor the long-term safety and efficacy of burosumab in adult patients with XLH that participated in previous clinical trials with burosumab (UX023-CL303 / UX023-CL304).

Detailed description: XLH is a rare, genetic disorder that is serious, chronically debilitating and represents an unmet medical need. XLH is the most common inherited form of rickets and the most common inherited defect in renal tubular phosphate transport. XLH is transmitted as an X-linked dominant disorder. Mutations resulting in the loss of function of PHEX form the genetic basis for XLH. More than 300 different PHEX gene mutations have been identified in patients with XLH (PHEXdb); however, few definitive correlations have been observed between specific mutations and phenotypic severity.

Patients with XLH have hypophosphatemia due to excessive serum FGF23 levels. FGF23 reduces serum phosphorus levels by two distinct mechanisms of action. The primary mechanism is to inhibit phosphate reabsorption in the proximal tubule of the kidney. The secondary mechanism is to decrease phosphate absorption by the small intestine through the inhibition of 1,25(OH)2D production in the kidney.

Burosumab has the potential to block or reduce FGF23 action and improve phosphate homeostasis in XLH patients. Burosumab binds the amino-terminal domain of FGF23 that interacts with the FGF-binding portion of the combination FGFR1/Klotho receptor, preventing FGF23 from binding to and signaling from its receptor. Both intact and fragmented FGF23 polypeptides are immunoprecipitated with burosumab. By inhibiting FGF23, burosumab restores tubular reabsorption of phosphate (as measured by the ratio of renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate \[TmP/GFR\]) from the kidney and increases the production of 1,25(OH)2D that also enhances intestinal absorption of phosphate. The dual action on kidney reabsorption and intestinal absorption improves serum phosphorus levels, which is expected to improve bone mineralization and reduce the diverse bone and non-bone manifestations associated with hypophosphatemia in XLH patients.

Eligibility criteria: Inclusion Criteria:

1. Subjects who provide written informed consent after the nature of the study has been explained, and prior to any research-related procedures.
2. Subjects who participated in Study UX023-CL303 or UX023-CL304. Any subjects that did not complete Study UX023-CL303 or UX023-CL304 may be included on a case-by-case basis. Subjects' enrolment is not dependent on any response to Primary or Secondary endpoints in studies UX023-CL303 or UX023-CL304.
3. Willing to provide access to prior medical records for the collection of historical growth, biochemical and radiographic data, and disease history.
4. Must, in the opinion of the investigator, be willing and able to complete all aspects of the study, adhere to the study visit schedule and comply with the assessments.
5. Females of child-bearing potential must have a negative urine pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not to be of child-bearing potential include those who have been in menopause for at least two years prior to Screening, or have had tubal ligation at least one year prior to Screening, or have had a total hysterectomy or bilateral salpingo-oophorectomy. If sexually active, male and female subjects must be willing to use one highly effective method of contraception for the duration of the study.

Exclusion Criteria:

1. Hypocalcemia or hypercalcemia, defined as serum calcium levels outside the age-adjusted normal limits and deemed as clinically significant in the opinion of the investigator.
2. Presence of a concurrent disease or condition that would interfere with study participation or affect safety in the opinion of the investigator or Sponsor.
3. Use of any investigational product other than burosumab or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
4. Subjects with major protocol deviations in Study UX023-CL303 or UX023-CL304 which in the view of the investigator places the subject at high risk of poor treatment compliance or of not completing the study.
5. Subjects who discontinued treatment from Study UX023-CL303 or UX023-CL304 due to either a grade ≥3 treatment-related hypersensitivity reaction or a burosumab-related hypersensitivity reaction reported as a SAE.

Primary outcomes:
measure: Proportion of subjects achieving mean serum phosphorus levels above the LLN (2.5mg/dL[0.81mmol/L]), as averaged across dose cycles between baseline and their last administered dose.
timeFrame: Serum phosphorous levels will be monitored from Screening and every 12 weeks until the end of the study, at approximately 144 weeks.
Secondary outcomes:
measure: Effect of burosumab on pre-existing pseudofracture healing will be monitored by centrally read targeted X-Ray
timeFrame: Targetted X-Rays at ongoing fracture sites will be taken at the End of Study Visit, approximately week 144.
measure: Effect of burosumab on patients walking ability measured using the 6 Minute Walk Test.
timeFrame: The 6MWT will be measured at Baseline and then every 12 weeks for the first 48 weeks and then every 24 weeks for up to 144 weeks
measure: Effect of burosumab on Patient mobility assessed using the Timed Up and Go Test (TUG).
timeFrame: The TUG Test will be assessed at Baseline and then every 12 weeks for the first 48 weeks and then every 24 weeks for up to 144 weeks
measure: Effect of burosumab on stiffness and physical function will be assessed using WOMAC.
timeFrame: The WOMAC questionnaire will be administered at Baseline and then every 12 weeks for 48 weeks and every 12 weeks for up to 48 weeks and then every 24 weeks for up to 96 weeks
measure: Effect of burosumab on patient's pain severity and the impact of pain on functioning will be assessed using the Short-form Brief Pain Inventory questionnaire.
timeFrame: The BPI will be administered at Baseline and then every 12 weeks for 48 weeks and then every 24 weeks for up to 144 weeks
measure: Effect of burosumab on patient's fatigue and the interference of fatigue on daily life over a 24 hour period.
timeFrame: The BFI will be administered at Baseline and then every 12 weeks for up to 48 weeks and then every 12 weeks for up to 144 weeks
measure: Effect of burosumab on bone metabolism and phosphate homeostasis using urinary phosphorus as PD marker.
timeFrame: Pharmacodynamic analysis will be conducted at Baseline and every 12 weeks for up to 88 weeks
measure: Effect of burosumab on enthesopathy will be monitored by centrally read targeted X-Ray.
timeFrame: Lateral foot views (bilateral) will be obtained at screening and at End of Study, approximately week 88.
measure: Effect of burosumab on bone metabolism and phosphate homeostasis using Serum Phosphorus as PD marker.
timeFrame: Pharmacodynamic analysis will be conducted at Baseline and every 12 weeks for up to 88 weeks.
measure: Effect of burosumab on bone metabolism and phosphate homeostasis using serum 1, 25(OH)2D as PD marker.
timeFrame: Pharmacodynamic analysis will be conducted at Baseline and every 12 weeks for up to 88 weeks.
measure: Effect of Burosumab on phosphate reabsorption as measured by the ratio of renal tubular maximum reabsorption rate of phosphate to glomerular filtrate [TmP/GFR].
timeFrame: Pharmacodynamic analysis will be conducted at Baseline and every 12 weeks for up to 88 weeks.
measure: Effect of burosumab on health related quality of life as measured by SF-36v2
timeFrame: The SF-36v2 will be administered at Baseline and then every 12 weeks for 48 weeks and then every 24 weeks for up to 144 weeks
Other outcomes:
Locations:
city: Le Kremlin-Bicêtre
country: France
facility: CHU de Bicetre
city: Paris
country: France
facility: Hopital Lariboisiere
city: Paris
country: France
facility: Hopital Cochin
city: Dublin
country: Ireland
facility: St. Vincent's University Hospital
city: Florence
country: Italy
facility: Azienda ospedaliera universitaria Careggi
city: Edinburgh
country: United Kingdom
facility: Western General Hospital
city: London
country: United Kingdom
facility: National Hospital for Neurology and Neurosurgery-University College London Hospitals NHS Foundation Trust
city: Oxford
country: United Kingdom
facility: Nuffield Orthopaedic Centre - Oxford University Hospitals Nhs Trust
city: Sheffield
country: United Kingdom
facility: Northen General Hospital
city: Stanmore
country: United Kingdom
facility: Royal National Orthopaedic Hospital NHS Trust
Study officials:
affiliation: CHU de Bicêtre
name: Peter Kamenicky
role: PRINCIPAL_INVESTIGATOR
References: